Wednesday, January 11, 2006

MedImmune inflates flu vaccine production capacity to boost market presence

11/01/2006 - MedImmune will soon ramp up production of its intranasal flu vaccine after the US Food and Drug Administration (FDA) approved its new and larger flu vaccine manufacturing facility in Speke, England.

The new facility is 10 times larger than MedImmune's existing manufacturing facility in Speke, and will allow the company to produce up to 15 million doses per month, or about 90 million doses per influenza manufacturing season, of its trivalent, intranasal flu vaccine, FluMist.
This is a mammoth increase in vaccine production considering the company only produced 3 million doses of FluMist this year and the decision to ramp up production may seem somewhat ambitious.

link to full article

No comments: